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Adipocyte fatty acid binding protein (aFABP, aP2) is a 14.6 kDa cytosolic protein located in adipocytes and macrophages and assists in
the intracellular transport of fatty acids. It is one of a class of fatty acid binding proteins (FABPs) that are found predominately in the
liver, heart, intestine and connective tissues. Hotamisligal et al. have reported that aFABP-deficient mice, when placed on a high fat diet
(40% of caloric intake as fat), were significantly protected from hyperinsulinemia and insulin resistance compared to the wild type.
Additional genetic experiments have been reported in which aFABP null mice have been crossed with ob/ob and in another instance
apoE-/- mice. The aFABP-deficient ob/ob mice were more insulin sensitive when compared to ob/ob controls as demonstrated measuring
Based on these genetic knock-out models, we pursued the development of inhibitors of
by circulating glucose and insulin levels.
aFABP for their therapeutic potential in the treatment of diabetes. Herein we disclose the synthesis of two azole inhibitors of P2 and the
methods used to prepare them
.
acid vantage point. By altering the modulation of energy stores
along the fatty acid axis an impact on circulating glucose levels
Introduction
would be expected. This strategy then provides a new basis for
With the spread of Western lifestyles, the prevalence of
therapy.
type 2 diabetes is rising. In the United State it is estimated that
nearly 21 million children and adults (7.0% of the population)
have diabetes. Of this number only 15 million are currently
diagnosed. Alarmingly, it is also estimated that there are
N
N
O
N
potentially 54 million people who are currently “pre-diabetic”.
This is a situation where glucose is only partially controlled. If
the situation is left unmanaged it is anticipated that these
O
O
individuals will ultimately exhibit the disease. Taken together,
O
there are 1.5 million new cases of diabetes being diagnosed in
OH
people aged 20 years or older (2005 data) within the United
States each year. The expectation is that these numbers are likely
Inhibitor 1
Inhibitor 2
to greatly increase in the near future.1
Ki = 6 nM
Ki = 1 nM
Diabetes is characterized by hyperglycemia and
Figure
1:Potent
Inhibitors
of
aP2
disturbances of carbohydrates, lipid and protein metabolism. As
these metabolic disturbances become “chronic,” a wide variety of
A promising new diabetes target for investigation is the
medical problems present themselves. Foremost among them
inhibition
of aP2.8 aP2 is one of a family of homologous
these are heart disease and stroke accounting for 65% of deaths in
intracellular fatty acid binding proteins that is involved in the
people with diabetes. In addition, a high percentage of diabetics
regulation of fatty acid trafficking. aP2 is found in adipocytes and
are afflicted with hypertension. Diabetic complications are not
mediates fatty acid fluxes in adipose tissue.9 Hotamisligal et al.
limited to cardiovascular concerns.
Diabetes also has a
have reported that aFABP deficient mice, when placed on a high
detrimental impact on the retina, kidney and nervous systems.
fat diet (40% of caloric intake as fat), were significantly protected
The disease becomes the basis for 24,000 new cases of blindness
from hyperinsulinemia and insulin resistance compared to the
annually, nearly half of new cases of kidney failure, and a major
wild type.10 Additional genetic experiments have been reported in
2
percentage of lower limb amputations; the total cost of the
which aFABP null mice have been crossed with ob/ob mice. The
disease is currently estimated at over 150 billion dollars in the
1
aFABP
deficient ob/ob mice were more insulin sensitive when
United States annually.
compared
to ob/ob controls as demonstrated measuring by
Current diabetes treatment strategies include: reducing
circulating
glucose and insulin levels.11 Supported by these
3
insulin resistance using glitazones, supplementing insulin
genetic knock-out models, aP2 inhibition presents itself as an
supplies with exogenous insulin,4 increasing insulin secretion
perfect target for the treatment of diabetes.9 Moreover, workers at
5
with sulfonyl ureas, and reducing hepatic glucose production
6
Harvard
and Bristol-Myers Squibb recently reported successful
with biguanides. Recently, treatment strategies using DPP-IV
7
intervention
with an aP2 inhibitor against a wide variety of
inhibitors and GLP-1 agonists
have also emerged. Of the
diabetes
markers
including fasting and parandial glucose levels in
aforementioned list, the mechanisms of action generally focus on
12
the
ob/ob
mouse.
treating type 2 diabetes predominately from the glucose/insulin
There are several reports of aP2 inhibitors in the
axis. However, there is currently no chemical agent that
11
these papers typically reveal binding affinities to aP2
literature;
addresses diabetes via altered energy homeostasis from the fatty
and very limited chemical synthetic procedures. Our goal was to
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prepare two known potent inhibitors of aP212 (Figure 1) and
disclose needed experimental details to provide access in
determining if these agents would serve as forerunners of a new
therapeutic class of anti-diabetic agents. For this reason the
preparation of the two compounds below was undertaken. They
both have high binding affinity to aP2. The first compound was
prepared according to the methods in Scheme 1. The second
compound was prepared as seen in Scheme 2.
Chemistry:
In Scheme 1, benzoin (3) was reacted with 2-bromobenzoic acid under standard conditions to give benzoin 2-bromobenzoate. The ester was reacted without purification and
immediately treated with ammonium acetate in acetic acid to
generate oxazole 4 (45% overall). Compound 4 smoothly
underwent palladium catalyzed cross coupling with 3-methoxy
phenyl boronic acid in 75% isolated yield. Deprotection of the
methyl group was achieved with BBr 3 to provide hydroxylbiphenyl 6. For this conversion, maintaining the reaction
temperature below 0 °C proved to be critical in the successful
transformation of the ether to the alcohol. Warmer temperatures
and prolonged reaction times generated multiple side products.
Isolated yields of the alcohol were around 55%. The final two
steps in generating the target inhibitor required coupling of the
phenol with ethyl bromoacetate (DMF and K 2 CO 3 , 65%),
followed by hydrolysis of the ester (KOH in alcohol 50%) to
provide the target molecule (1). Isolation of the salt was
accomplished with the agency of SP207 gel column
chromatography.

phosphine under Suzuki conditions generating biphenyl 10. The
yields of the reaction tended to vary but averaged around 70%.
The methyl ether in 10 was deprotected with boron tribromide
with reaction temperatures below˚C0 to liber ate phenol 11
(yields 35%-50%). The target molecule 2 was prepared by
K 2 CO 3 /DMF and ethyl bromoacetate coupling followed by base
hydrolysis. Overall conversions were around 35% for the last
two procedures.
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Scheme 2: a. NH 4 OAc, HOAc, 2-bromo-benzaldelhye; b. ethyl iodide,
K 2 CO 3 ; c. methoxyphenyl boronic acid, Pd(PPh 3 ) 4 , Na 2 CO 3 ; d. BBr 3 , -5
°C; e. ethyl bromoacetate, K 2 CO 3 ; f. NaOH
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Scheme 1: a. (COCl) 2 , 2-bromobenzoic acid; b.NH 4 OAc, HOAc, Δ; c.
methoxyphenyl boronic acid, Pd(PPh 3 ) 4 , Na 2 CO 3 ; d. BBr 3 , -5 °C; e.
ethyl bromoacetate, K 2 CO 3 ; f. NaOH.

Compound 2 was prepared as outlined in Scheme 2. 2Bromo-benzaldelhyde was reacted with diketone 8 to form an
imidazole. The imidazole ring was then alkylated with ethyl
iodide in the presence of K 2 CO 3 to give 9 (65% overall).
Compound 9 was reacted with palladium (0) tetrakistriphenyl-

Reagents were purchased from Aldrich Chemical (P.O.
Box 2060 Milwaukee, WI 53201) and used without further
purification. All column chromatography was carried out using
ACROS silica gel 0.20 -0.50 mm, pore diameter – 4 nm. TLC
was carried out on Merk Silica Gel Plates with a UV binder.
Typical visualization was accomplished by UV, I 2 or KMnO 4
staining. 1H NMR was carried out on an Anasazi EFT-60 MHz
Spectrometer referenced to TMS. HPLC was carried out using
Waters 1525 HPLC. Column: Waters X-Terra Phenyl: pore 5um,
length 4.6X150mm. UV detection at 220 and 245 nm. A linear
gradient from 100% solvent A to 100% solvent B was run from
time 0 min. to time 16 min. Solvent A: (water:methanol:acetic
acid; 9/1/.025), Solvent B (water:methanol:acetic acid; 1/9/.025).
SP207 gel was purchased from Sorbent Technologies (2377 John
Glen Dr. Atlanta, GA 30341) and used after washing with
solutions of NaOH, HCl, water, methanol, and acetone. The resin
was stored over a solution of very dilute NaHCO 3 :methanol
solution (95:5 v/v).
Preparation of 2-(2-bromophenyl)-4,5-diphenyl-1,3-oxazole
(3).
A solution of 2-bromobenzoic acid (5.00 g, 24.77
mmol) and dichloromethane (50 mL) was treated with oxalyl
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chloride (3.81g, 30.00 mmol) and dimethyl formamide (5 drops).
The reaction mixture was stirred until all gas evolution has
stopped (0.5 h). The mixture was stripped on a rotoevaporator
and the remaining acid chloride diluted with dichloromethane
(100 mL). The slight yellow solution was mixed with benzoin
(4.64 g, 22.00 mmol) and triethylamine (7.50, 75.00 mmol). The
mixture was stirred overnight and diluted with water. The layers
were separated and the dichloromethane fraction washed with
Na 2 CO 3 solution and then KHSO 4 . The organics were dried
over MgSO 4 and concentrated to give the ketoester as a colorless
oil.
The crude ester (3.60 g, @ 9.4 mmol) from above was
mixed with ammonium acetate (3.60 g, 47 mmol) and acetic acid
(35 mL). The mixture was brought to reflux for 4 h and cooled to
ambient temperature. The organics were diluted with ethyl
acetate and water. The layers equilibrated and separated. The
organic fraction was washed with water, NaHCO 3 , brine, dried
(MgSO 4 ) and concentrated to give yellow oil. The oil was
recrystalized from a small volume of hot methanol to give the
desired oxazole (2.20 g, 61%). TLC (1:3 ethyl acetate/hexane)
R f = 0.4; 1H NMR (CDCl 3 ) δ 8.20 -6.90 (m, 14 H) ppm.
Preparation of 2-(2-(3-methoxyphenyl)-phenyl)-4,5-diphenyl1,3-oxazole (4).
Nitrogen was bubbled through a solution of 3 (0.29 g,
0.78 mmol), 3-methoxy-phenyl boronic acid (0.15 g, 0.98 mmol)
and aqueous Na 2 CO 3 (0.7 mL, 2M) in toluene (3 mL) and
ethanol
(0.85mL) for about 10 min.
Tetrakis
(triphenylphosphine) palladium (0) (50 mg) was added and the
reaction was heated in an oil bath set at ˚C
77 for 14 h. The
mixture was cooled and diluted with ethyl acetate (25 mL) and
the organics were washed with water, NaHCO 3 , dried and
concentrated. The remainder was purified on silica gel column
chromatography with 1:5 ethyl acetate in hexanes as a mobile
phase. The procedure provided 0.27 g (85%) of the title
compound. TLC (1:3 ethyl acetate/hexane) R f = 0.7; 1H NMR
(CDCl 3 ) δ 8.20 -6.90 (m, 18 H), 3.50 (s, 3H) ppm.
2'-(4,5-diphenyl-1,3-oxazol-2-yl)biphenyl-3-ol (5).
To a solution of 4 (0.25 g, 0.62 mmol) in anhydrous
dichloromethane at -10˚C was added boron tribromide in
dichloromethane dropwise (2M, 0.65 mL). The reaction was
stirred at -5˚C for 1 h and quenched with aqueous NaHCO 3
solution and the pH adjusted to 6 with dilute HCl. The mixture
was diluted with ethyl acetate and the organics separated from the
aqueous fraction. The organics were washed with brine, dried
over MgSO 4 and concentrated. The remainder was purified on
silica gel column chromatography with dichloromethane and then
10% ethyl acetate/dichloromethane to give the title compound
(0.10 g, 55%). TLC (1:3 ethyl acetate/hexane) R f = 0.3; 1H NMR
(CDCl 3 ) δ 8.20 -7.00 (m, 18 H), 1.90 (s broad, 1H) ppm.
Ethyl [[2'-(4,5-diphenyl-1,3-oxazol-2-yl)biphenyl-3yl]oxy]acetate (6).
A 25 mL RB flask was charged with DMF (2.5 mL),
K 2 CO 3 (0.055 g, 0.04 mmol), ethyl bromoacetate (0.038 g, 0.02
mmol) and compound 5 (0.080 g; 0.20 mmol). The biphasic

mixture was stirred overnight and diluted sequentially with ethyl
acetate 15 mL and water 15 mL. The layers were separated and
the organic fraction was washed with water, dried over Na 2 SO 4
and concentrated. The remainder was purified by silica gel
column chromatorgray with ethyl acetate and hexanes as a mobile
phase. A gradient elution from hexane to 25% ethyl acetate in
hexane provided the title compound. (0.80 g, 50%-85%). TLC
(1:3 ethyl acetate/hexane) R f = 0.5; 1H NMR (CDCl 3 ) δ 7.90 6.80 (m, 18 H), 4.60 (s, 2H), 4.20 (q, 2H, J=7.5 Hz), 1.60 (t, 3H,
J=7.5 Hz) ppm.
[[2'-(4,5-diphenyl-1,3-oxazol-2-yl)biphenyl-3-yl]oxy]acetic
acid, sodium form (1) Inhibitor 1.
A 25 mL RB flask was charged with ethanol (7 mL),
NaOH (0.4 g, 10 mmol), compound 6 (0.80 g, 0.16 mmol) and 1
mL of water. The mixture was heated to reflux for 6 h and
cooled to room temperature. The mixture was concentrated and
purified on SP207 gel using a step gradient with 100 mL volumes
starting with water; 10% methanol in water; 20% methanol in
water; 30% methanol in water; 50% methanol in water; 75 %
methanol in water; 90% methanol in water; and methanol to
give 0.18 g of final product. TLC (1:3 ethyl acetate/hexane) R f =
0.05; HPLC: Retention Time: 15.4 min. 1H NMR (CD 3 OD) δ
7.90 -6.80 (m, 18 H), 4.50 (s, 2H) ppm.
2-(2-bromophenyl)-4,5-diphenyl-1H-imidazole (8a).
Benzil (8) (4.20 g, @ 20.0 mmol) was mixed with
ammonium acetate (14.40 g, 188 mmol), acetic acid (45 mL) and
2-bromo-benzaldehyde (3.70 g, 20.0 mmol). The mixture was
brought to reflux for 14 h and cooled to ambient temperature.
The organics were diluted with a large volume of water and a
white solid formed. The solid was collected by filtration and
dried overnight. After standing overnight the material maintained
a strong acetic acid odor. The solid was then triturated with water
and filtered three times to remove any acetic acid and/or
ammonium salts. The solid collected provided the title compound
(6.20 g, 83%). TLC (1:3 ethyl acetate/hexane) R f = 0.5; 1H NMR
(CDCl 3 ) δ 8.20-7.20 (m, 14 H), 1.80 (s broad, 1H) ppm.
2-(2-bromophenyl)-1-ethyl-4,5-diphenyl-1H-imidazole (9).
To a mixture of 8a (2.5 g; 6.70 mmol), K 2 CO 3 (1.33 g;
10.00 mmol) and DMF (20 mL) was added ethyl iodide (1.40 g;
8.80 mmol). The mixture was stirred overnight and diluted with
water. After vigorous stirring a white solid was formed. The
solid was collected by filtration and dried overnight. The
material was triturated with water two times and the resulting
solid collected by filtration. The solid collected provided the title
compound (2.19 g, 82%). TLC (1:3 ethyl acetate/hexane) R f =
0.6; 1H NMR (CDCl 3 ) δ 7.80 -7.00 (m, 14 H), 3.75 (q, 2H,
J=11.5 Hz), 0.95 (t, 3H, J=11.5 Hz) ppm.
1-ethyl-2-(3'-methoxybiphenyl-2-yl)-4,5-diphenyl-1Himidazole (10).
Nitrogen was bubbled through a solution of 9 (0.35 g,
0.81 mmol), 3-methoxy-phenyl boronic acid (0.15 g, 0.98 mmol)
and aqueous Na 2 CO 3 (0.7 mL, 2M) in toluene (3 mL) and
ethanol (0.85 mL) for about 10 min.
Tetrakis
(triphenylphosphine) palladium (0) (50 mg) was added and the
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reaction was heated in an oil bath set at
˚C77
for 14 h. The
mixture was cooled and diluted with ethyl acetate (25 mL) and
the organics were washed with water, NaHCO 3 , dried and
concentrated. The remainder was purified on silica gel column
chromatography with 1:5 ethyl acetate in hexanes as a mobile
phase. The procedure provided (0.23 g, 61%) of the title
compound. TLC (1:3 ethyl acetate/hexane) R f = 0.8; 1H NMR
(CDCl 3 ) δ 7.80-6.90 (m, 18 H), 3.60 (s, 2H), 3.20 (q, 2H, J=8.5
Hz), 0.60 (t, 3H, J=8.5 Hz) ppm.
1-ethyl-2-(3'-hydroxybiphenyl-2-yl)-4,5-diphenyl-1Himidazole (11).
To a solution of 10 (0.25 g, 0.62 mmol) in anhydrous
dichloromethane at -10 ˚C was added boron tribromide in
dichloromethane drop wise (2M, 0.65 mL). The reaction was
stirred at -10˚C for 90 min. and quenched with methanol (2 mL).
The mixture was stirred for 1 h at RT. and the pH adjusted to 7
with dilute NaHCO 3 solution. The mixture was diluted with
ethyl acetate and the organics separated from the aqueous
fraction. The organics were washed with brine, dried over
MgSO 4 and concentrated. The remainder was purified on silica
gel column chromatography with dichloromethane and then 10%
ethyl acetate/dichloromethane to give the title compound (0.13 g,
50%). R f = 0.3; 1H NMR (CDCl 3 ) δ 7.80-6.90 (m, 18 H), 3.30 (q,
2H, J=8.5 Hz), 2.10 (s broad, 1H), 0.70 (t, 3H, J=8.5 Hz) ppm.
ethyl [[1-ethyl-2-4,5-diphenyl-1H-imidazole]biphenyl-3yl]oxy]acetate (12).
A 25 mL RB flask was charged with DMF (2.5 mL),
K 2 CO 3 (0.055 g, 0.04 mmol), ethyl bromoacetate (0.038 g, 0.02
mmol) and compound 11 (0.10 g; 0.22 mmol). The biphasic
mixture was stirred overnight and was diluted sequentially with
ethyl acetate 15 mL and water 15 mL. The layers were separated
and the organic fraction was washed with water, dried over
Na 2 SO 4 and concentrated. The remainder was purified by silica
gel column chromatography with ethyl acetate and hexanes as a
mobile phase. A gradient elution from hexane to 25% ethyl
acetate in hexane provided the title compound. (0.80 g, 70%). R f
= 0.6; 1H NMR (CDCl 3 ) δ 7.90-6.90 (m, 18 H), 4.60 (s, 2H), 4.20
(q, 2H, J=7 Hz) 3.30 (q, 2H, J=9 Hz), 1.70 (t, 3H, J=7 Hz), 0.60
(t, 3H, J=9 Hz) ppm.
[[1-ethyl-2-4,5-diphenyl-1H-imidazole]biphenyl-3-yl]oxy]
acetic acid, sodium form (2) Inhibitor 2.
A 25 mL RB flask was charged with ethanol (7 mL),
NaOH (0.4 g, 10 mmol), compound 12 (0.10 g, 0.16 mmol) and 1
mL of water. The mixture was heated to reflux for 1 h and
cooled to room temperature. The mixture was concentrated and
purified on SP207 gel using a step gradient with 100 mL volumes
starting with water; 10% methanol in water; 20% methanol in
water; 30% methanol in water; 50% methanol in water; methanol
in water; 90% methanol in water; methanol to give 0.09 g of
final product. R f = 0.05; HPLC: Retention Time: 15.0 min. 1H
NMR (CD 3 OD) δ 7.90-6.90 (m, 18 H), 4.60 (s, 2H), 3.30 (q, 2H,
J=9 Hz), 0.60 (t, 3H, J=9 Hz) ppm.

Herein we have described the preparation of two
inhibitors of aP2. The methods disclosed are suitable to generate
milligram to gram quantities of these inhibitors. All of the
reactions are robust and give fair to excellent yields of products.
A key component to the isolation of the final salts is the
utilization of SP-207 resin. This resin provides a convenient
system for preparative reverse phase isolation of organic salts.
Herein the isolation of these fatty acid salts was demonstrated.
The synthesis of these potent inhibitors has been
accomplished and it is intended that further utilization of these
unique compounds will enhance our understanding of diabetes
and new treatments for the disease. This rationale is consistent
with the information reported by Hotamisligil utilizing the ob/ob
mouse model. These animals suffer from severe obesity and very
high glucose levels. In this animal model, the aP2 inhibitors not
only reduced glucose levels but also demonstrated increased
sensitivity to insulin. The Harvard results suggest that new
diabetic treatments could be forthcoming by interference of the
fatty acid trafficking pathway.
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